Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Total Non-Current Liabilities (2020)

Tango Therapeutics has reported Total Non-Current Liabilities over the past 1 years, most recently at $168.6 million for Q4 2020.

  • Quarterly results put Total Non-Current Liabilities at $168.6 million for Q4 2020, changed N/A from a year ago — trailing twelve months through Dec 2020 was $168.6 million (changed N/A YoY), and the annual figure for FY2020 was $168.6 million, changed.
  • Total Non-Current Liabilities for Q4 2020 was $168.6 million at Tango Therapeutics.
  • Over the last five years, Total Non-Current Liabilities for TNGX hit a ceiling of $168.6 million in Q4 2020 and a floor of $168.6 million in Q4 2020.